



Forum for
Collaborative HIV Research

HCV

D **RU**G

R **ES**ISTANCE

A **D**VISORY

G **R**OU

March 24, 2009



HISTORY

- Purpose: bring together parties interested in and working in HCV drug resistance to discuss issues pertinent to HCV drug development and resistance testing
 - Outgrowth of proposal at the 1st International Workshop on Hepatitis C: Resistance and New Compounds (October, 2006)
 - *Ad hoc* group approached the Forum for Collaborative HIV Research for organizational support
 - Composition: representatives from industry, academics and regulatory agencies
- Goals:
 - Produce consensus recommendations of appropriate methodology for HCV resistance testing
 - For drug development
 - For clinical practice
 - Provide scientific guidance to facilitate discussion between industry and regulatory agencies in areas of HCV drug resistance



HISTORY

- 1st meeting: May 18, 2007, Washington, DC
 - Identified and classified questions/issues:
 - Formed working groups
 - ◉ Sequence Analysis Working Group (SAWG)
 - ◉ Phenotype Working Group (PWG)
 - ◉ Clinical Working Group (CWG)
 - ◉ Other (eg, Database)
- 2nd meeting: Nov 2, 2007, Boston, MA
 - Progress reports and discussion from three working groups
 - ◉ SAWG and PWG encouraged to proceed toward preparation of manuscripts
 - ◉ HCV DRAG presentation at 2007 HepDART meeting
 - ◉ Continued discussion of clinical issues
 - Decision to move toward formation of Database Working Group
- 3rd meeting: February 13, 2008, Paris, France
 - 3 HCV databases represented
 - ◉ Japanese, European and Los Alamos
 - Discussion on collaborative approaches for HCV resistance db



PROGRESS

- Presentations
 - HCV Resistance Workshop, Nov 2007
 - HepDart, Dec 2007
 - EASL Hep B and C Resistance Conference, Feb 2008
- Manuscripts
 - SAWG
 - ◉ October 2008: First draft assembled and delivered to OC after multiple versions and telecons between SAWG members
 - ◉ Oct 2008 - Jan 2009: Editing by HCV DRAG OC members
 - ◉ March 2009: Penultimate draft sent to SWAG members and OC members for final comments/editing
 - ◉ April 2009: Target submission date
 - ◉ Target journal: *Gastroenterology*
 - PWG
 - ◉ Draft manuscript in preparation
 - ◉ Target journal and date: tbd



TODAY'S MEETING

- Consideration of drug resistance in the drug development process and clinical trial design
 - Lessons learned
 - Regulatory perspective
 - Persistence and long-term follow-up
- HCV: where virology and hepatology intersect
- HCV databases
 - Resistance literature repository
 - HCV sequences
- HCV resistance CME



NEXT STEPS

- New leader for phenotype working group
- Reorganization of clinical working group
- Create ResistLit DB WG (*Resistance Literature Database working group*)
- Create HCV resistance CME working group
- Next steps on collaborative HCV resistance database
- Publication of meeting outcomes (manuscript #3)
- Next meeting (autumn 2009)
 - Focus topic



PROCESS

- Define issue and questions
- Categorize into one of following:
 1. Immediate recommendation needed to guide process in right direction
 2. Recommendation based on discussions within working groups and between WG's and DRAG
 3. Multiple possibilities to be described by working group with pro/con and context
 4. Insufficient data/methodology at this time, noted as issue